Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
2023年10月2日 - 10:00PM
ビジネスワイヤ（英語）
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), a life sciences company that is focused on the
development of immunologic based therapies for the prevention and
treatment of disease, today announced the appointment of Lakhmir
Chawla M.D. to the Company’s Board of Directors (Board).
“We are excited to welcome Dr. Chawla as an independent director
to our Board,” said James Rolke, Chief Executive Officer of
Revelation. “Dr. Chawla brings decades of expertise and leadership
in key areas such as nephrology, critical care medicine, drug
development and strategic implementation. I am confident that he
will provide valuable perspectives as we continue to execute our
strategy of developing safe, effective therapies for patients in
need.”
“I am delighted to join the Revelation Board,” said Dr. Chawla.
“The Company approaches medicine with a unique mix of
entrepreneurial spirit, scientific rigor, and deep medical
knowledge. With a passion for innovation and improving clinical
outcomes for patients, I look forward to partnering with
Revelation’s team.”
Dr. Chawla is currently the Chief Executive Officer of Stavro
Medical. Previously, Dr. Chawla was the Chief Medical Officer of
Silver Creek Pharma where he oversaw the Acute Ischemic Stroke
development program and initiation of the ARPEGGIO neuroprotection
study. Prior to that, Dr. Chawla was the Chief Medical Officer at
La Jolla Pharmaceutical Company where he oversaw the development
and conduct of the Phase 3 ATHOS-3 trial. Prior to joining La
Jolla, Dr. Chawla was a Professor of Medicine at the George
Washington University, where he had dual appointments in the
Department of Anesthesiology and Critical Care Medicine and in the
Department of Medicine, Division of Renal Diseases and
Hypertension. Dr. Chawla is an internationally renowned expert in
the field of acute kidney injury (AKI) and shock. He is the author
of over 160 peer-reviewed publications and a recipient of the
International Vicenza Award for Critical Care Nephrology; an award
that recognizes individuals who have made seminal clinical research
advancements that have significantly improved the care of
critically ill patients with AKI and have been adopted worldwide.
He remains an active investigator in the fields of AKI biomarkers,
AKI risk prediction, AKI therapeutics and chronic kidney disease
caused by AKI.
Dr. Chawla joins the Revelation Board on the recent retirement
from the Board of Curt LaBelle M.D. Dr. LaBelle served on the Board
for over two years and the Company thanks him for his years of
dedicated service.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused
on the development of immunologic-based therapies for the
prevention and treatment of disease. Revelation has multiple
product candidates in development that are based on the
well-established biology of phosphorylated hexaacyl disaccharide
(PHAD) and its effect on the innate immune system. REVTx‑300 is
being developed as a potential therapy for the treatment of acute
and chronic organ disease including CKD, AKI and myocarditis.
REVTx‑100 is being developed as a prevention and treatment of
infection.
For more information on Revelation, please visit
www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate", "believe", "expect",
"estimate", "plan", "outlook", and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that the Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
clinical utility of an increase in intranasal cytokine levels as a
biomarker of viral infections; the ability to successfully complete
planned clinical studies of its product candidates; the risk that
we may not fully enroll our clinical studies or enrollment will
take longer than expected; risks relating to the occurrence of
adverse safety events and/or unexpected concerns that may arise
from data or analysis from our clinical studies; changes in
applicable laws or regulations; expected initiation of the clinical
studies, the timing of clinical data; the outcome of the clinical
data, including whether the results of such study is positive or
whether it can be replicated; the outcome of data collected,
including whether the results of such data and/or correlation can
be replicated; the timing, costs, conduct and outcome of our other
clinical studies; the anticipated treatment of future clinical data
by the FDA, the EMA or other regulatory authorities, including
whether such data will be sufficient for approval; the success of
future development activities for its product candidates; potential
indications for which product candidates may be developed; the
potential impact that COVID-19 may have on Revelation’s suppliers,
vendors, regulatory agencies, employees and the global economy as a
whole; the ability of Revelation to maintain the listing of its
securities on NASDAQ; investor sentiment relating to SPAC related
going public transactions; the expected duration over which
Revelation’s balances will fund its operations; and other risks and
uncertainties described herein, as well as those risks and
uncertainties discussed from time to time in other reports and
other public filings with the SEC by Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002690894/en/
Sandra Vedrick Vice President, Investor Relations & Human
Resources Revelation Biosciences Inc. Email:
svedrick@revbiosciences.com
and
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 12 2024 まで 1 2025
Revelation Biosciences (NASDAQ:REVB)
過去 株価チャート
から 1 2024 まで 1 2025
